Sign up to save your podcasts
Or
Share Why quantum will not scale without diagnostics
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Why quantum will not scale without diagnostics
What if the real bottleneck in quantum is not building the chip, but learning why it fails?
In this episode, I unpack the key learnings from Part 2 of my deep dive with Johannes Jobst, CEO of QuantaMap. One of my biggest takeaways is that quantum may need its own process control and diagnostics layer before the industry can truly scale. Building a few quantum chips in a lab is one thing. Building thousands of high quality chips with repeatable performance and acceptable yield is something very different.
This episode is for investors, founders, and anyone trying to understand what it will take for quantum to move from lab to fab. In semiconductors, scaling did not happen through transistor innovation alone. It also required decades of progress in inspection, metrology, yield learning, process control, and manufacturing feedback loops. Quantum is only beginning that journey.
That is what makes this conversation so important. If yield remains low and failure analysis stays slow, scaling becomes much harder. Without a real diagnostics layer, every failed chip stays a mystery instead of becoming a learning cycle. The companies that help the industry learn, improve, and manufacture quantum chips reliably at scale may end up becoming one of the most important layers in the value chain.
đź’ˇ In this episode, we cover:
Why diagnostics may be a critical missing layer in quantum manufacturing
Why quantum scaling needs more than better qubits
How cryogenic inspection changes what chipmakers can actually learn
Why room-temperature measurements often miss the real problem
How process control, yield learning, and feedback loops could shape quantum manufacturing
Why “business as usual” is still one of the biggest bottlenecks in the market
How QuantaMap thinks about becoming a deeply embedded diagnostics layer
What investors should watch as quantum moves from lab to fab
Chapters
00:00 Why chip diagnostics matters in quantum
00:44 How QuantaMap’s cryogenic measurement works
04:27 Why multimodal imaging matters
06:15 Why process control comes later
08:09 Why cryogenic scanning matters
15:29 Business as usual is the real competition
20:42 Barriers to entry and customer lock-in
23:44 The ASML-style ambition
28:57 Diagnostics as a service and tool sales
34:44 Why timing from lab to fab matters
46:53 What would increase conviction
51:13 Why QuantaMap matters in the value chain
🔗 Resources / Links 🎧 Listen to all episodes →
https://open.spotify.com/show/7HZpSCz1w7a782e1B26MYA?si=JjJ7gTAfRGaZwnYwMa65mQ
Share this episode with someone investing in or building in quantum, and make sure to subscribe or follow Beyond the Qubit for more conversations on quantum technology, markets, and investing.
đź“Ś Disclaimers: This is not investment advice. I do this under my personal name and do not represent any company.
View all episodes
By Frank DekkerWhat if the real bottleneck in quantum is not building the chip, but learning why it fails?
In this episode, I unpack the key learnings from Part 2 of my deep dive with Johannes Jobst, CEO of QuantaMap. One of my biggest takeaways is that quantum may need its own process control and diagnostics layer before the industry can truly scale. Building a few quantum chips in a lab is one thing. Building thousands of high quality chips with repeatable performance and acceptable yield is something very different.
This episode is for investors, founders, and anyone trying to understand what it will take for quantum to move from lab to fab. In semiconductors, scaling did not happen through transistor innovation alone. It also required decades of progress in inspection, metrology, yield learning, process control, and manufacturing feedback loops. Quantum is only beginning that journey.
That is what makes this conversation so important. If yield remains low and failure analysis stays slow, scaling becomes much harder. Without a real diagnostics layer, every failed chip stays a mystery instead of becoming a learning cycle. The companies that help the industry learn, improve, and manufacture quantum chips reliably at scale may end up becoming one of the most important layers in the value chain.
đź’ˇ In this episode, we cover:
Why diagnostics may be a critical missing layer in quantum manufacturing
Why quantum scaling needs more than better qubits
How cryogenic inspection changes what chipmakers can actually learn
Why room-temperature measurements often miss the real problem
How process control, yield learning, and feedback loops could shape quantum manufacturing
Why “business as usual” is still one of the biggest bottlenecks in the market
How QuantaMap thinks about becoming a deeply embedded diagnostics layer
What investors should watch as quantum moves from lab to fab
Chapters
00:00 Why chip diagnostics matters in quantum
00:44 How QuantaMap’s cryogenic measurement works
04:27 Why multimodal imaging matters
06:15 Why process control comes later
08:09 Why cryogenic scanning matters
15:29 Business as usual is the real competition
20:42 Barriers to entry and customer lock-in
23:44 The ASML-style ambition
28:57 Diagnostics as a service and tool sales
34:44 Why timing from lab to fab matters
46:53 What would increase conviction
51:13 Why QuantaMap matters in the value chain
🔗 Resources / Links 🎧 Listen to all episodes →
https://open.spotify.com/show/7HZpSCz1w7a782e1B26MYA?si=JjJ7gTAfRGaZwnYwMa65mQ
Share this episode with someone investing in or building in quantum, and make sure to subscribe or follow Beyond the Qubit for more conversations on quantum technology, markets, and investing.
đź“Ś Disclaimers: This is not investment advice. I do this under my personal name and do not represent any company.